Mostrar el registro sencillo del ítem
dc.contributor.author | Arnaldos-Carrillo, María | |
dc.contributor.author | Noguera-Velasco, José Antonio | |
dc.contributor.author | Martínez-Ardil, Isabel M | |
dc.contributor.author | Riquelme-Pérez, Alejandro | |
dc.contributor.author | Cebreiros-López, Iria | |
dc.contributor.author | Hernández-Vicente, Álvaro | |
dc.contributor.author | Ros-Lucas, José Antonio | |
dc.contributor.author | Khan, Amjad | |
dc.contributor.author | Bayes-Genís, Antoni | |
dc.contributor.author | Pascual-Figal, Domingo A | |
dc.date.accessioned | 2024-05-10T10:21:34Z | |
dc.date.available | 2024-05-10T10:21:34Z | |
dc.date.issued | 2023-09-08 | |
dc.identifier.citation | Med Clin (Barc). 2023 Sep 8;161(5):185-191. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19358 | |
dc.description.abstract | BACKGROUND Soluble suppressor of tumorigenicity-2 (sST2) is a biomarker for heart failure and pulmonary injury. We hypothesize that sST2 could help predict severity of SARS-CoV-2 infections. METHODS sST2 was analyzed in patients consecutively admitted for SARS-CoV-2 pneumonia. Other prognostic markers were also measured. In-hospital complications were registered, including death, ICU admission, and respiratory support requirements. RESULTS 495 patients were studied (53% male, age: 57.6±17.6). At admission, median sST2 concentrations was 48.5ng/mL [IQR, 30.6-83.1ng/mL] and correlated with male gender, older age, comorbidities, other severity biomarkers, and respiratory support requirements. sST2 levels were higher in patients who died (n=45, 9.1%) (45.6 [28.0, 75.9]ng/mL vs. 144 [82.6, 319] ng/mL, p<0.001) and those admitted to ICU (n=46, 9.3%) (44.7 [27.5, 71.3] ng/mL vs. 125 [69.0, 262]ng/mL, p<0.001). sST2 levels>210ng/mL were a strong predictor of complicated in-hospital courses, with higher risk of death (OR, 39.3, CI95% 15.9, 103) and death/ICU (OR 38.3, CI95% 16.3-97.5) after adjusting for all other risk factors. The addition of sST2 enhanced the predictive capacity of mortality risk models. CONCLUSIONS sST2 represents a robust severity predictor in COVID-19 and could be an important tool for identifying at-risk patients who may benefit from closer follow-up and specific therapies. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Interleukin-1 Receptor-Like 1 Protein | es_ES |
dc.subject.mesh | COVID-19 | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Aged | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Prognosis | es_ES |
dc.subject.mesh | SARS-CoV-2 | es_ES |
dc.subject.mesh | Biomarkers | es_ES |
dc.title | Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 37137804 | es_ES |
dc.format.volume | 161 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | 185 | es_ES |
dc.identifier.doi | 10.1016/j.medcli.2023.04.005 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1578-8989 | es_ES |
dc.relation.publisherversion | 10.1016/j.medcli.2023.04.005 | es_ES |
dc.identifier.journal | Medicina clinica | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionales | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |